Drug Trial Radar · NCT01474798
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Feb 29, 2012
Primary completion
Oct 31, 2012
Study completion Dec 31, 2012
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 91-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe acne vulgaris. Ten (10) subjects will receive RA-18C3 via subcutaneous injection. Subjects will receive injections at Days 0, 21, and 42 for a total of 3 injections. Study drug will be administered under close observation in a facility equipped to handle medical emergencies. Subjects will not be discharged from the facility until at least 1 hour following the injection or 1 hour after their vital signs have stabilized. Safety will be assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and the recording of adverse clinical events.
Conditions
- Acne Vulgaris
Interventions
RA-18C3Drug
For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection. For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: 100 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Moy, Fincher, and Chipps Facial Plastics and Dermatology
Beverly Hills, California
Meridien Research
St. Petersburg, Florida
Austin Dermatology Associates
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.